Overview
- A bipartisan group of senators introduced the Pharmaceutical Investment Oversight and Accountability Act during a Senate Special Committee on Aging hearing to increase transparency over foreign investment in U.S. pharmaceutical and biotech firms.
- The bill would require the Federal Trade Commission, working with the Committee on Foreign Investment in the United States, to deliver annual reports to Congress that assess how foreign investment affects domestic drug production, supply‑chain resilience, and DNA sequencing or storage technologies.
- Witnesses at the hearing warned that China has moved beyond generic manufacturing into biotech research, clinical trials and data holdings, creating long‑term competitiveness and security concerns for the U.S. industry.
- Experts urged stronger rules to require companies in strategic health sectors to disclose beneficial owners and foreign control, and they recommended expanding review powers so transactions, licensing deals and data arrangements cannot evade scrutiny.
- Several witnesses proposed concrete policy responses such as diversifying production through partnerships with India and using U.S. development finance tools to support trusted manufacturers, noting that heavy offshoring of active pharmaceutical ingredients has left U.S. patients, especially seniors, exposed to supply disruptions.